ARCHIVES

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

NCI Programs: Institute Seeks White Papers On Technology

September 11, 1998

International Working Group Suggests Earlier Endpoints For HPV Vaccine Trials

August 29, 2014

Regulatory Agencies: FDA To Increase Fees For Mammography Facility Inspections

January 30, 1998

DCBDC Advisors Set aside $2 Mil. For Research On The Microenvironment of Breast Cancer

July 9, 1993

Professional Societies: ASCO Develops Cancer Genetics Curriculum

December 18, 1998